Bilaal.Raja
Company record

HCAT  Health Catalyst, Inc.

Trailing twelve months to 2026-06-30, as filed 2026-08-06 and not restated since.
Technology

Scale

Market cap
$131m
Revenue TTM
$292m
Net income TTM
$-265m
Free cash flow
$27m
Composite score
35.9
Sector rank
#2997

Valuation

P / E
EV / EBITDA
EV / sales
0.6
FCF yield
20.70%
Yield vs 10-yr
-207.59pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.79% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-90.6%
EBITDA margin
-67.7%
ROE
-262.6%
ROIC
-165.2%
Revenue growth
-7.5%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

The decrease in revenue was primarily due to our exit of certain lower margin TEMS arrangements and churn related to the migration from DOS to Ignite. • We incurred net losses of $40.5 million and $41.0 million for the three months ended June 30, 2026 and 2025, respectively, and $151.6 million and $64.7 million for the six months ended June 30, 2026 and 2025, respectively. We benefit from a highly recurring revenue model, in which greater than 90% of our revenue is recurring in nature, and a high level of technology revenue predictability. Technology gross margin decreased from 50% for the three months ended June 30, 2025 to 48% for the three months ended June 30, 2026. …Health Catalyst, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →